Medical Myeloma Treatment: Uncover Key Prognosis & Survival Factors

Introduction & Epidemiology

Multiple Myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow, leading to monoclonal protein production and various organ dysfunctions. As an Academic Orthopedic Surgeon and Medical Educator, our focus is predominantly on the skeletal manifestations of this pervasive disease, which significantly impact patient morbidity, quality of life, and overall management strategy.

Epidemiologically, MM is the second most common hematologic malignancy, with an incidence of approximately 4-5 per 100,000 persons per year. It primarily affects older adults, with a median age at diagnosis around 70 years. Skeletal involvement is a hallmark of MM, with over 80% of patients presenting with osteolytic lesions, pathological fractures, or diffuse osteopenia at some point during their disease course. These skeletal-related events (SREs) include pathological fractures (vertebral compression fractures, long bone fractures), spinal cord compression, hypercalcemia, and intractable bone pain.

Orthopedic surgical intervention plays a critical role in managing these SREs. The goals of surgical management in MM patients are primarily palliative and supportive: to alleviate pain, restore or preserve neurological function, provide mechanical stability to prevent or treat pathological fractures, and ultimately improve the patient's quality of life and functional independence. Effective management of SREs also facilitates the continuation of systemic anti-myeloma therapies, which are crucial for disease control and overall survival.

The prognosis and survival factors in MM are complex and multifactorial. While the International Staging System (ISS) and Revised ISS (R-ISS) primarily rely on biochemical markers (albumin, beta-2 microglobulin, LDH, cytogenetics), the occurrence and successful management of SREs indirectly but profoundly impact these factors. For instance, preventing spinal cord compression preserves neurological function, avoiding devastating complications like paralysis and deep vein thrombosis (DVT), which can significantly shorten life expectancy. Stabilizing a pathological fracture allows for mobility and better performance status, enabling patients to tolerate more aggressive systemic therapies. Therefore, orthopedic surgical intervention, while not directly treating the underlying malignancy, is an integral component of comprehensive care that influences patient outcomes and overall survival in MM.

Surgical Anatomy & Biomechanics

Understanding the unique anatomical and biomechanical challenges presented by myeloma-affected bone is paramount for successful surgical planning and execution. Myeloma lesions typically manifest as osteolytic defects, leading to significant structural compromise.

Spinal Anatomy & Biomechanics

The vertebral column, a common site for myeloma involvement, consists of 33 vertebrae, providing support, mobility, and protection for the spinal cord.
* Vertebral Structure: Each vertebra comprises an anterior vertebral body and a posterior neural arch (pedicles, laminae, spinous process, transverse processes). Myeloma preferentially targets the highly vascularized red marrow within the vertebral bodies, leading to lytic destruction and collapse.
* Spinal Cord & Neural Elements: The spinal cord runs within the vertebral canal, protected by the bony elements. Compression can arise from vertebral collapse, tumor expansion into the canal, or epidural hematoma. Understanding the dermatomal and myotomal distributions is crucial for neurological assessment.
* Denis Three-Column Concept: Divides the spine into anterior (anterior longitudinal ligament, anterior 2/3 of vertebral body, annulus), middle (posterior 1/3 of vertebral body, posterior longitudinal ligament), and posterior (posterior elements, supraspinous, interspinous, ligamentum flavum) columns. Involvement of two or more columns signifies instability, often requiring surgical stabilization. Myeloma frequently compromises the anterior and middle columns.
* Biomechanics of Spinal Stability: The spine functions as a load-bearing column. Lytic lesions reduce the bone's modulus of elasticity and ultimate compressive strength. Fixation in myeloma-affected spine often requires longer constructs, cement augmentation of pedicle screws, and consideration for anterior column reconstruction if severe kyphosis or complete vertebral body destruction is present. The compromised bone quality makes traditional screw purchase unreliable.

Long Bone Anatomy & Biomechanics

Long bones, particularly the femur and humerus, are frequent sites of pathological fractures due to myeloma.
* Cortical & Medullary Structure: The diaphysis consists of thick cortical bone surrounding a medullary canal. Metaphyses and epiphyses have thinner cortices and more trabecular bone. Myeloma lesions are typically intramedullary, expanding and thinning the cortex from within.
* Muscle Attachments & Neurovascular Bundles: Awareness of major muscle origins and insertions is crucial for surgical approaches and post-operative rehabilitation. Proximity of neurovascular structures (e.g., radial nerve in the humeral diaphysis, sciatic nerve in proximal femur) necessitates careful dissection.
* Weight-Bearing Considerations: Lower extremity long bones (femur, tibia) bear significant loads, making internal fixation of pathological fractures particularly challenging in osteopenic bone. Upper extremity bones (humerus) bear less axial load but require robust fixation for functional use.
* Biomechanics of Fracture Fixation: In myeloma-affected bone, the host bone contributes minimally to load sharing. Implants must often carry the entire load. This necessitates stronger implants (e.g., larger diameter nails), longer constructs, and often cement augmentation (intracavitary cement, cement-augmented screws) to achieve stable fixation in compromised bone. Stress risers, often at the junction of healthy and diseased bone or at implant ends, are prone to subsequent fracture.

Indications & Contraindications

Surgical decision-making in MM patients with SREs requires careful consideration of the patient's overall health, disease burden, prognosis, and the specific nature of the skeletal lesion. The primary goals are pain relief, functional preservation, and neurological protection.

General Principles

• Multidisciplinary Approach: Collaboration with hematology/oncology, radiation oncology, pain management, and palliative care specialists is essential.
• Patient Status: Performance status (e.g., ECOG scale), systemic disease activity, and life expectancy heavily influence the aggressiveness of surgical intervention.
• Goals of Surgery: Rarely curative, typically palliative – aiming to improve quality of life, maintain function, and enable continued systemic therapy.

Operative Indications

1. Pathological Fractures:
   • Long Bones (Femur, Humerus, Tibia): Displaced or unstable fractures affecting weight-bearing or functional limbs. These are often severely comminuted due to poor bone quality.
   • Unstable Vertebral Fractures: Fractures involving two or more columns of Denis, leading to spinal instability, progressive kyphosis, or intractable axial pain unresponsive to conservative measures.
2. Impending Pathological Fractures:
   • Significant osteolytic lesions in critical load-bearing bones (e.g., proximal femur, femoral diaphysis, humerus) at high risk of fracture. The Mirels Score is a widely used tool, with a score of 7 or higher generally considered an indication for prophylactic stabilization, especially in the lower extremities. This score assesses pain, lesion size, site, and type of lesion.
3. Spinal Cord Compression or Cauda Equina Syndrome:
   • Any evidence of neurological deficit (motor weakness, sensory loss, bowel/bladder dysfunction) due to spinal cord or cauda equina compression from tumor mass or vertebral collapse is a surgical emergency. Timely decompression is crucial to preserve or restore neurological function.
4. Intractable Pain:
   • Localized severe pain unresponsive to systemic analgesia, radiation therapy, and other non-operative measures, especially if related to a specific structural instability or impending fracture.
5. Progressive Deformity:
   • Development of significant kyphosis or scoliosis secondary to vertebral collapse, leading to functional impairment or pain.
6. Non-union of Pathological Fractures:
   • Failure of a pathological fracture to heal following initial non-operative or operative management, causing persistent pain or instability.

Non-Operative Indications

1. Stable Vertebral Compression Fractures (VCFs):
   • Painful VCFs without neurological compromise or significant instability, often managed with vertebroplasty or kyphoplasty (considered minimally invasive surgical procedures), bracing, analgesics, and radiation therapy.
2. Asymptomatic Lesions:
   • Skeletal lesions without pain, impending fracture risk (Mirels < 7), or neurological compromise are typically monitored and managed with systemic anti-myeloma therapy and potentially radiation.
3. Low Mirels Score Impending Fractures:
   • Lesions with a Mirels score less than 7, indicating a lower risk of fracture, can often be observed and managed with systemic therapy and focal radiation.
4. Poor Performance Status / Limited Life Expectancy:
   • Patients with extremely poor ECOG performance status (3 or 4), rapidly progressive systemic disease, or very limited life expectancy where the morbidity of surgery outweighs potential benefits. Palliative care and comfort measures take precedence.
5. Diffuse Bone Involvement:
   • Extremely widespread lytic disease with no single dominant lesion amenable to effective surgical fixation, particularly in patients with short life expectancy.

Contraindications

• Profound Coagulopathy: Uncorrectable bleeding diathesis that poses an unacceptable risk of intraoperative hemorrhage or hematoma formation.
• Unstable Medical Comorbidities: Severe cardiac, pulmonary, or renal dysfunction precluding safe anesthesia and surgical recovery.
• Rapidly Progressive Systemic Disease: Where local orthopedic intervention would not significantly improve quality of life or survival, and recovery from surgery is unlikely.
• Overwhelming Disease Burden: Diffuse, rapidly progressive disease where the patient is moribund and comfort care is the primary focus.
• Active Infection: Uncontrolled systemic or local infection.

TABLE: Operative vs. Non-Operative Indications for Myeloma-Related SREs

Pre-Operative Planning & Patient Positioning

Thorough pre-operative planning is crucial for optimizing outcomes and mitigating risks in MM patients, who often present with complex medical issues and compromised bone quality.

Multidisciplinary Approach

Effective management requires a coordinated effort:
* Hematology/Oncology: Optimizing systemic disease control, managing chemotherapy schedules, assessing overall prognosis.
* Anesthesiology: Evaluating cardiorespiratory reserve, renal function, optimizing fluid and blood management, planning for post-operative pain control.
* Radiation Oncology: Planning for pre- or post-operative radiation therapy for local control or pain relief.
* Pain Management: Establishing a robust pre- and post-operative pain management strategy, especially given chronic pain often experienced by MM patients.
* Nephrology: For patients with myeloma nephropathy, optimizing renal function, considering dialysis, and managing fluid/electrolyte balance.

Patient Assessment & Optimization

1. Performance Status: Evaluate using ECOG or Karnofsky scales. This is a primary determinant of surgical candidacy and prognosis.
2. Systemic Disease Assessment: Understand the stage of myeloma, current treatment regimen, response to therapy, and any active complications (e.g., hypercalcemia, renal failure).
3. Renal Function: Myeloma nephropathy is common. Assess creatinine, GFR. Avoid nephrotoxic agents pre- and intraoperatively. Hydration is key.
4. Coagulation Status: Myeloma can cause acquired coagulopathies (e.g., factor deficiencies, hyperviscosity syndrome, platelet dysfunction). Assess CBC, PT/INR, PTT, platelet count. Correct any deficiencies pre-operatively.
5. Anemia: Common in MM. Transfuse to optimize hemoglobin if necessary, especially for anticipated blood loss.
6. Nutritional Status: Assess for cachexia, provide nutritional support if needed.
7. Bone Health: Continue bisphosphonates or RANKL inhibitors (denosumab) as per hematologist's guidance, though some may hold for a period around major surgeries to avoid osteonecrosis of the jaw (ONJ) or atypical fractures, depending on the drug and duration of use. Prophylactic antibiotics for ONJ risk if tooth extraction is needed.

Imaging

• Plain Radiographs: Baseline assessment of lesion extent, fracture configuration.
• Computed Tomography (CT): Provides detailed osseous anatomy, cortical integrity, fracture patterns, and aids in surgical planning (e.g., screw trajectory, construct length). CT angiography may be useful for pre-operative embolization planning.
• Magnetic Resonance Imaging (MRI): Essential for assessing soft tissue tumor extension, epidural involvement, spinal cord compression, and marrow infiltration.
• PET/CT: Useful for whole-body staging, identifying active lesions, and guiding biopsy or focal treatment.
• Bone Scan: Less sensitive for purely lytic myeloma lesions, but can identify other areas of increased osteoblastic activity.

Pre-operative Interventions

• Biopsy: If diagnosis is uncertain or to confirm progression, a needle biopsy (image-guided) may be performed pre-operatively. Intraoperative biopsy is also an option.
• Embolization: For highly vascular lesions (less common in myeloma compared to renal cell carcinoma or thyroid cancer metastases, but can occur), pre-operative arterial embolization may reduce intraoperative blood loss.
• Radiation Therapy: Neoadjuvant radiation can shrink tumor bulk and alleviate pain, sometimes converting a complex case to a more manageable one, or to sterilize the lesion site, especially for spinal cord compression if surgical decompression is not immediately feasible. Adjuvant radiation is often planned post-operatively for local control.
• Pain Management: Aggressive pre-operative pain control improves patient comfort and reduces anesthetic requirements.
• Steroids: For spinal cord compression, high-dose corticosteroids (e.g., Dexamethasone) should be initiated immediately to reduce edema around the spinal cord.

Informed Consent

Realistic discussions regarding surgical goals (often palliative), potential complications (higher in these compromised patients), expected functional recovery, and integration with systemic therapy are paramount.

Patient Positioning

• Spine Surgery: Typically prone position on a radiolucent table (Jackson table, OSI table) to allow for fluoroscopy and maintain abdominal pressure off-loading to reduce epidural venous bleeding. Meticulous padding of pressure points is crucial due to osteopenia and general fragility.
• Long Bone Surgery: Dependent on the specific bone and approach (e.g., supine for femoral nailing, lateral for hip, beach chair or supine for humerus). Careful attention to stable positioning, neurovascular protection, and skin integrity is essential in osteopenic patients.

Detailed Surgical Approach / Technique

Surgical intervention for myeloma-related SREs requires meticulous technique, adaptability to compromised bone quality, and often a deviation from standard orthopedic trauma principles. The overarching goal is stable fixation, pain relief, and functional preservation.

General Principles

• Palliative vs. Curative: Most orthopedic procedures for MM are palliative, aimed at improving quality of life, not curing the disease. Radical resection with wide margins, though standard for primary bone sarcomas, is rarely appropriate or feasible for diffuse MM.
• Compromised Bone Quality: Myeloma-affected bone is osteolytic, osteopenic, and mechanically weak. Expect poor screw purchase and implant pull-out.
• Cement Augmentation (PMMA): Polymethylmethacrylate (PMMA) cement is frequently used to augment screw fixation, fill lytic defects, and enhance stability, particularly in the spine and around long bone implants. It provides immediate stability and heat-induced tumor necrosis.
• Load Sharing: Construct design should aim for load sharing between the implant and the host bone to the extent possible, though often the implant must bear a greater proportion of the load. Longer constructs often provide better stability in compromised bone.
• Biopsy: Always obtain a specimen for pathological confirmation, even if a previous diagnosis exists, to rule out transformation or mixed lesions.
• Hemostasis: Expect increased bleeding due to hypervascularity of lesions and potential coagulopathies. Meticulous hemostasis and careful blood product management are vital.

Spinal Stabilization

1. Vertebroplasty / Kyphoplasty

• Indications: Painful, stable VCFs, often in the thoracic and lumbar spine, without neurological deficits or significant posterior wall compromise.
• Technique: Percutaneous, image-guided (fluoroscopy or CT) transpedicular approach.
  • Vertebroplasty: Injection of low-viscosity PMMA into the collapsed vertebral body.
  • Kyphoplasty: A balloon tamps are inflated within the vertebral body to create a cavity and attempt to restore vertebral height before PMMA injection.
• Internervous Planes: Minimal, as this is a percutaneous procedure, targeting the vertebral body through the pedicle.
• Considerations: Risk of cement extravasation into the spinal canal, neural foramen, or vasculature. Careful monitoring of cement flow is essential.

2. Posterior Spinal Decompression & Stabilization

• Indications: Spinal cord compression, unstable pathological fractures (e.g., Denis Type B/C), progressive kyphosis, intractable axial pain. Often performed in the thoracolumbar spine.
• Approach: Midline posterior incision, subperiosteal dissection of paraspinal muscles (internervous plane: between multifidus and longissimus, or erector spinae group if more lateral). Expose the laminae, facets, and transverse processes.
• Decompression: Direct posterior decompression via laminectomy is often insufficient for anterior epidural compression from myeloma. A costotransversectomy or transpedicular approach may be necessary to decompress the anterior spinal cord and remove tumor.
• Fixation: Pedicle screw fixation, extending typically two levels above and two levels below the affected segment for sufficient lever arm and stability. Due to osteopenia, cement augmentation of pedicle screws (injecting PMMA into the vertebral body around the screw) is highly recommended, especially in the cephalad and caudal healthy-ish vertebrae.
• Reconstruction: If extensive anterior column destruction (corpectomy), posterior instrumentation can be combined with anterior column reconstruction using an expandable cage or PMMA fill.
• Considerations: Increased blood loss. Intraoperative neuromonitoring (SSEP, MEP) is advisable.

3. Anterior Spinal Stabilization (e.g., Thoracic/Lumbar Corpectomy)

• Indications: Large anterior tumor burden, severe kyphosis from anterior column collapse, situations where posterior decompression is inadequate, or when anterior column support is critical. Often combined with posterior stabilization.
• Approach:
  • Thoracic: Left thoracotomy (4th-6th intercostal space) to access the thoracic spine.
  • Lumbar: Retroperitoneal approach (left flank incision) to access the lumbar spine.
• Decompression & Resection: Corpectomy (resection of vertebral body) and tumor debulking.
• Reconstruction: Placement of an expandable cage, allograft, or custom PMMA construct to restore anterior column height and stability. Anterior plating may be used.
• Considerations: More extensive approach, higher morbidity. Requires meticulous vascular and visceral dissection.

Long Bone Fixation (Femur, Humerus)

1. Intramedullary Nailing

• Indications: Preferred for pathological fractures or impending fractures of the femoral diaphysis, proximal femur, humerus, and tibia. Provides axial alignment and load sharing.
• Technique: Standard reamed or unreamed IM nailing.
  • Cement Augmentation: Before nail insertion, intracavitary PMMA cementation of the lytic lesion (filling the defect with cement) can significantly improve stability, especially in the proximal or distal ends of long bones. The nail is then inserted through the cement. Locking screws are essential.
  • Prophylactic Nailing: For impending fractures, the entire bone at risk is often nailed to prevent future fractures (e.g., full-length femur nailing for proximal femur lesion).
• Internervous Planes:
  • Femur: Trochanteric entry (through gluteus medius/minimus internervous plane) or piriformis fossa entry (gluteus maximus split).
  • Humerus: Deltoid split (between anterior and middle deltoid heads, respecting axillary nerve).
• Considerations: Risk of thermal necrosis from cement polymerization if not carefully managed. Ensure adequate reaming to facilitate cement flow.

2. Plating

• Indications: Metaphyseal fractures, periarticular fractures, situations where IM nailing is not anatomically feasible (e.g., very wide medullary canal, extensive tumor near a joint, specific humeral shaft fractures not amenable to IMN).
• Technique: Principles of bridge plating apply. Screws must gain purchase in healthy bone proximal and distal to the lesion.
  • Cement Augmentation: Augmentation with PMMA around screws or by filling the lytic defect before plate application. Locking plates are preferred as they do not rely on plate-bone compression and provide angular stability in osteopenic bone.
• Internervous Planes: Dependent on the specific bone and location (e.g., direct lateral approach to femur, anterolateral approach to humerus).
• Considerations: Requires more extensive soft tissue dissection than IM nailing. Potential for stress risers at plate ends.

3. Endoprosthetic Reconstruction

• Indications: Extensive bone loss involving a joint (e.g., proximal femur, proximal humerus, distal femur), failed internal fixation, or severe bone destruction precluding standard osteosynthesis.
• Technique: Resection of the involved segment of bone and reconstruction with a modular tumor endoprosthesis. This can replace portions of the femur, humerus, or other bones.
• Considerations: High upfront stability. Higher rates of infection and mechanical loosening compared to primary joint replacements. Complex reconstruction, often requires specific tumor prosthesis components.

Complications & Management

Myeloma patients undergoing orthopedic surgery are at a heightened risk for complications due to their systemic disease, compromised immune status, impaired bone quality, and often, advanced age.

Intraoperative Complications

• Hemorrhage: Myeloma lesions can be hypervascular, and patients may have baseline coagulopathies or thrombocytopenia.
  • Incidence: Significant blood loss (requiring transfusion) can occur in 10-30% of cases.
  • Salvage Strategies: Meticulous hemostasis, use of hemostatic agents (topical thrombin, bone wax), pre-operative embolization if highly vascular, intraoperative cell salvage, rapid transfusion of blood products and clotting factors, tranexamic acid.
• Neurological Injury: Direct trauma to spinal cord or peripheral nerves during decompression, instrumentation, or malpositioning.
  • Incidence: 1-5% in spinal surgery.
  • Salvage Strategies: Intraoperative neuromonitoring (SSEP, MEP), careful dissection, removal of offending implant/fragment, immediate revision surgery.
• Cement Extravasation: PMMA cement leakage into the spinal canal, neural foramen, or vascular structures during vertebroplasty/kyphoplasty or screw augmentation.
  • Incidence: Varies widely (5-20% for vertebroplasty, symptomatic less than 1%).
  • Salvage Strategies: Meticulous technique, high-viscosity cement, real-time fluoroscopic monitoring, stopping injection if extravasation detected. Surgical decompression if neurological deficit occurs.

Early Post-operative Complications

• Infection (Surgical Site Infection - SSI): Immunocompromised state, prolonged surgery, and indwelling hardware contribute to increased risk.
  • Incidence: 5-15%, higher than elective orthopedic surgery.
  • Salvage Strategies: Prophylactic broad-spectrum antibiotics, meticulous surgical technique, aggressive wound management. If superficial, antibiotics and wound care. If deep, surgical debridement, culture-directed intravenous antibiotics, possible implant removal (in two-stage revision for periprosthetic infection).
• Thromboembolism (DVT/PE): Cancer patients are hypercoagulable, combined with surgery and immobility.
  • Incidence: 5-15% without prophylaxis.
  • Salvage Strategies: Pharmacological prophylaxis (LMWH, DOACs) and mechanical prophylaxis (intermittent pneumatic compression, early mobilization). Anticoagulation if DVT/PE confirmed.
• Systemic Complications: Renal insufficiency (myeloma nephropathy exacerbation), cardiac events, pneumonia, uncontrolled hypercalcemia.
  • Incidence: Variable, depends on baseline health.
  • Salvage Strategies: Close medical monitoring, aggressive hydration, nephrology/cardiology consultation, optimization of medical comorbidities, respiratory support, biphosphonates/denosumab for hypercalcemia.
• Wound Complications: Hematoma, dehiscence, necrosis.
  • Incidence: 5-10%.
  • Salvage Strategies: Meticulous closure, use of drains, careful soft tissue handling, local wound care, surgical debridement if necrosis or persistent dehiscence.

Late Post-operative Complications

• Local Disease Progression/Recurrence: Myeloma is a systemic disease; local control is not always durable.
  • Incidence: ~15-20% within 2 years of local treatment.
  • Salvage Strategies: Adjuvant radiation therapy (often planned), initiation or change in systemic anti-myeloma therapy. Revision surgery if progression causes new pain, instability, or neurological deficit.
• Implant Failure: Due to poor bone quality, progression of lysis, pseudoarthrosis, or inadequate initial fixation.
  • Incidence: Can be high, 10-30% for some constructs, especially in load-bearing areas or with extensive lytic disease.
  • Salvage Strategies: Revision surgery (re-fixation with stronger construct, longer implants, cement augmentation, conversion to endoprosthesis), bracing.
• Non-union/Malunion: Impaired bone healing due to underlying disease, systemic therapies (chemotherapy, radiation), poor vascularity, or inadequate fixation.
  • Incidence: 10-25%.
  • Salvage Strategies: Revision surgery with re-fixation, possible bone grafting (less effective in MM), biological adjuncts (limited evidence), cement augmentation.
• Adjacent Segment Failure (Spine): Increased stress on adjacent levels after spinal fusion, leading to new VCFs or instability.
  • Incidence: 5-10% per year post-fusion.
  • Salvage Strategies: Conservative management, vertebroplasty/kyphoplasty, or extension of fusion construct.

TABLE: Common Complications, Incidence, and Salvage Strategies

Post-Operative Rehabilitation Protocols

Post-operative rehabilitation for MM patients is critical for maximizing functional recovery, alleviating pain, and integrating surgical gains with ongoing systemic therapies. Protocols must be individualized, considering the extent of surgery, stability of fixation, patient's baseline functional status, and overall disease progression.

General Principles

• Pain Management: Myeloma patients often have chronic pain. A multimodal pain management strategy is essential, combining opioids, NSAIDs (with caution for renal function), neuropathic agents, and local modalities. Aggressive pain control facilitates early mobilization.
• Early Mobilization: As soon as safely possible, to prevent complications such as DVT/PE, pneumonia, skin breakdown, and deconditioning.
• Weight-Bearing Restrictions: Dictated by the stability of fixation and the bone quality. This must be clearly communicated to the patient and therapists.
• Physical Therapy (PT) & Occupational Therapy (OT): Essential for restoring range of motion, strength, gait, and activities of daily living (ADLs).
• Coordination with Oncology: Rehabilitation must integrate seamlessly with systemic anti-myeloma treatments and potential adjuvant radiation.

Spinal Surgery Rehabilitation

• Early Post-Op (Days 1-7):
  • Mobilization: Out of bed within 24-48 hours. Start with sitting, then standing, short walks with assistance.
  • Bracing: Often prescribed for initial support, especially for extensive fusions, poor bone quality, or patient non-compliance. Type (TLSO, LSO) and duration are surgeon-dependent, typically 6-12 weeks, sometimes longer.
  • Pain Management: Aggressive, multimodal.
  • PT/OT: Education on spinal precautions (log-roll technique for bed mobility, avoid twisting/bending/lifting), assistive device training.
• Intermediate Post-Op (Weeks 2-12):
  • Activity: Progressive increase in ambulation and light daily activities. Avoid heavy lifting, twisting, or vigorous exercise.
  • PT: Focus on core stability exercises, postural re-education, gentle range of motion within pain limits. Avoid axial loading and excessive lumbar flexion.
  • Brace Weaning: Gradual weaning of bracing as pain improves and stability is confirmed clinically and radiographically.
• Late Post-Op (After 3 Months):
  • Activity: Gradually increase activity levels, guided by pain and healing. May return to low-impact exercise.
  • PT: Advanced strengthening, endurance training. Continued emphasis on spinal hygiene.
  • Long-Term: Patients should understand the need for lifelong spinal precautions and regular follow-up.

Long Bone Fixation Rehabilitation (e.g., Femur, Humerus)

• Early Post-Op (Days 1-7):
  • Mobilization: Initiate range of motion (ROM) for adjacent joints.
  • Weight-Bearing (Lower Extremity): Often initially non-weight-bearing (NWB) or touch-down weight-bearing (TDWB) for pathological fractures of the femur/tibia, progressing as callus formation and pain allow. Prophylactic fixations may allow earlier, protected weight-bearing.
  • Weight-Bearing (Upper Extremity): Early, protected ROM of shoulder/elbow. Sling for comfort/protection in humerus fractures.
  • Pain Management: Multimodal.
  • PT/OT: Instruction on assistive devices (crutches, walker), transfer training, education on weight-bearing restrictions.
• Intermediate Post-Op (Weeks 2-12):
  • Weight-Bearing Progression: Gradual progression from TDWB to partial weight-bearing (PWB) and then full weight-bearing (FWB) as per surgeon's discretion, based on radiographic signs of healing and stability. This may be slower than for traumatic fractures due to compromised bone.
  • PT: Progressive strengthening of surrounding muscles, ROM exercises. Gait training for lower extremity.
• Late Post-Op (After 3 Months):
  • Activity: Continue progressive strengthening and functional training. Return to activities as tolerated.
  • Expected Healing: Myeloma patients may have delayed or incomplete fracture healing due to systemic factors (disease itself, chemotherapy, radiation). Non-union rates can be higher. This needs to be managed with patient expectations.

Endoprosthetic Reconstruction Rehabilitation

• Often more aggressive rehabilitation: Endoprostheses typically provide immediate mechanical stability, allowing for earlier and potentially full weight-bearing and full range of motion compared to internal fixation, assuming soft tissue healing.
• Specific Protocols: Determined by the surgeon and type of implant. Close monitoring for infection and mechanical loosening.
• PT/OT: Focus on rapid restoration of strength, ROM, and functional use.

Coordination with Oncology and Long-Term Management

• Systemic Therapy Resumption: Rehabilitation needs to align with the hematologist/oncologist's plan for resuming or initiating systemic anti-myeloma therapy.
• Adjuvant Radiation: If planned, this may influence the timing and intensity of rehabilitation.
• Monitoring: Regular clinical and radiographic follow-up to monitor implant stability, disease progression, and development of new SREs.
• Bone Health: Continued use of bisphosphonates or denosumab, as indicated by the oncologist, for bone strengthening and prevention of new SREs.
• Psychosocial Support: Myeloma is a chronic, often debilitating disease. Patients benefit from psychological support, social work, and palliative care integration.

Summary of Key Literature / Guidelines

The management of skeletal-related events in multiple myeloma is guided by a confluence of orthopedic oncology principles, hematology/oncology guidelines, and evidence from specialized literature.

• National Comprehensive Cancer Network (NCCN) Guidelines: These are foundational for the multidisciplinary management of multiple myeloma. They provide comprehensive recommendations for diagnosis, risk stratification, systemic therapy, and management of SREs. For orthopedic surgeons, the NCCN guidelines emphasize a multidisciplinary approach, timely intervention for impending and actual pathological fractures, and the critical role of surgery in addressing spinal cord compression. They advocate for appropriate imaging (MRI for cord compression, CT for bone detail), and the use of adjuncts like radiation therapy and bone-modifying agents (bisphosphonates, denosumab).

• Mirels Score: Published by Mirels in 1989, this scoring system remains a widely accepted and validated tool for assessing the risk of impending pathological fractures in long bones. It assigns points (1-3) based on four factors:

  1. Site: Upper extremity (1), lower extremity (2), peritrochanteric (3)
  2. Pain: Mild (1), moderate (2), functional (3)
  3. Lesion Size: <1/3 cortical destruction (1), 1/3-2/3 cortical destruction (2), >2/3 cortical destruction (3)
  4. Type of Lesion: Blastic (1), mixed (2), lytic (3)
     A total score of 7 or higher generally indicates a high risk of fracture, warranting prophylactic surgical stabilization, particularly for weight-bearing bones like the femur. While not specific to myeloma, it is highly applicable to any metastatic lytic lesion.

• Surgical Oncology Principles for Metastatic Bone Disease: The general principles for managing metastatic bone disease are highly relevant to myeloma. These include the judicious use of internal fixation versus endoprosthetic reconstruction, the importance of achieving stable fixation in compromised bone, and the role of PMMA cement augmentation. Literature consistently supports the use of IM nailing for long bone diaphyseal fractures and impending fractures, and modular endoprostheses for extensive periarticular lesions or failed internal fixation.

• Role of Radiation Therapy (XRT): Radiation oncology plays a crucial adjunctive role. Pre-operative XRT can shrink tumor, alleviate pain, and potentially sterilize the surgical field (though less common for myeloma compared to some other solid tumors). Post-operative XRT is frequently used for local disease control, to sterilize residual microscopic disease, and reduce pain. Studies have shown that combining surgery with post-operative radiation can improve local control rates.

• Advancements in Systemic Therapy: The landscape of MM treatment has evolved dramatically with the introduction of novel agents, including proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (e.g., thalidomide, lenalidomide, pomalidomide), monoclonal antibodies (e.g., daratumumab, elotuzumab, isatuximab), and CAR T-cell therapies. These advancements have significantly improved overall survival (OS) for MM patients, leading to increased patient longevity and a greater need for durable orthopedic solutions. This improved survival also means that the benefits of preventing SREs through surgery (e.g., preventing paralysis, maintaining mobility) have an even greater impact on the patient's long-term quality of life and ability to tolerate extended systemic treatment regimens.

• Prognostic Factors and Survival Impact of SREs: While specific surgical intervention is not typically listed as a primary prognostic factor in the R-ISS, the successful management and prevention of SREs profoundly affect a patient's functional status, pain level, and ability to receive systemic therapy. Maintaining a good performance status (e.g., ECOG 0-2) is consistently associated with better overall survival in MM. Orthopedic surgery, by preventing devastating SREs like spinal cord compression or debilitating long bone fractures, directly contributes to maintaining this performance status, thus indirectly improving overall survival and quality of life. The literature supports that unresolved SREs contribute significantly to morbidity, prolonged hospitalization, and diminished quality of life, which can ultimately impair the ability to undergo critical systemic anti-myeloma treatments.

• Multidisciplinary Tumor Boards: The complexity of MM necessitates a multidisciplinary approach. Regular tumor board discussions involving orthopedic surgeons, hematologist/oncologists, radiation oncologists, radiologists, and pathologists are essential for developing individualized, optimal treatment plans that balance local control with systemic disease management and patient-specific factors.

In conclusion, orthopedic surgical management of skeletal-related events in multiple myeloma is a critical component of comprehensive patient care. By addressing instability, neurological compromise, and intractable pain, orthopedic surgeons enable patients to maintain functionality, improve their quality of life, and continue to benefit from life-prolonging systemic therapies, thereby influencing overall prognosis and survival.